Prostate brachytherapy

Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference

Retrieved on:

Tuesday, June 27, 2023

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.

Key Points:

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.
The authors reported that Cesium-131 prostate brachytherapy provided disease-free survival rates of 97.8% and 96%, at 5 and 10 years respectively.
“We’re excited that a presentation of long-term clinical data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ABS meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer.
He added, “The data shows Cesium-131 brachytherapy offers prostate cancer patients the prospect of disease-free survival of 96% ten years after treatment.

Isoray Announces Third Quarter Fiscal 2021 Financial Results

Retrieved on:

Thursday, May 13, 2021

Medicine, Clinical medicine, Medical physics, Brachytherapy, Prostate cancer, Prostate brachytherapy, IsoRay, Iridium

b'RICHLAND, Wash., May 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2021 ended March 31, 2021.\nRevenue for the third quarter of fiscal 2021 declined 10% to $2.60 million versus the record $2.88 million in the prior year comparable period.

Key Points:

b'RICHLAND, Wash., May 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2021 ended March 31, 2021.\nRevenue for the third quarter of fiscal 2021 declined 10% to $2.60 million versus the record $2.88 million in the prior year comparable period.
However, third quarter prostate increased 7% sequentially from the second quarter of fiscal 2021.
Prostate brachytherapy represented 78% of total revenue for the third quarter of fiscal 2021 compared to 84% in the prior year comparable period.
Prostate brachytherapy represented 79% of total revenue for the first nine months of fiscal 2021 compared to 87% for the first nine months of fiscal 2020.

DGAP-News: Eckert & Ziegler: Seed Implantation for Prostate Cancer Receives Reimbursement for Outpatient Care

Retrieved on:

Tuesday, January 12, 2021

Medicine, Clinical medicine, Medical physics, Anatomy, Brachytherapy, Prostate, Radiation therapy, Minimally invasive procedure, Prostate brachytherapy

Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany.

Key Points:

Seed implantation for prostate cancer is now to be reimbursed as an outpatient treatment by public health insurances in Germany.
Seed implantation or so called LDR brachytherapy is an organ-preserving, minimally invasive radiation procedure.
In this procedure, millimeter-sized, low-level radioactive titanium tubes are inserted into the prostate while protecting the surrounding tissue.
In Germany, inpatient seed brachytherapy has been included in the reimbursement catalog of health insurance companies since 2004.

C4 Imaging Announces Sirius Positive Signal MRI Marker Given FDA 510(k) Clearance for Use with Isoray’s Cesium-131 Brachytherapy Seeds to Treat Prostate Cancer

Retrieved on:

Tuesday, January 5, 2021

Medicine, Clinical medicine, Anatomy, Medical physics, Histopathology, Prostate cancer, Brachytherapy, Prostate, Magnetic resonance imaging, Prostate brachytherapy, Management of prostate cancer

Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used to facilitate brachytherapy seed localization within the prostate utilizing a single post-implant MRI procedure.

Key Points:

Sirius is implanted during the treatment of prostate cancer with brachytherapy and is used to facilitate brachytherapy seed localization within the prostate utilizing a single post-implant MRI procedure.
This allows the benefits of MRI assisted brachytherapy, also known as MRI assisted radiosurgery or MARS, to be made available to all prostate cancer patients treated with brachytherapy.
This is a significant milestone, said Andrew Bright, President and CEO of C4 Imaging.
Sirius MRI Markers will enable Isorays customers to fully utilize the benefits of MRI seed localization.

Isoray Announces First Quarter Fiscal 2021 Financial Results

Retrieved on:

Tuesday, November 10, 2020

Medicine, Clinical medicine, Medical physics, Brachytherapy, IsoRay, Prostate cancer, Prostate brachytherapy

RICHLAND, Wash., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2021 ended September 30, 2020.

Key Points:

RICHLAND, Wash., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the first quarter fiscal 2021 ended September 30, 2020.
Revenue for the first quarter of fiscal 2021 grew 3% to $2.38 million versus $2.32 million in the prior year comparable period.
Prostate brachytherapy represented 79% of total revenue for the first quarter of fiscal 2021 compared to 90% in the prior year comparable period.
Isoray CEO Lori Woods said, Our fiscal first quarter 2021 is representative of the current dynamics within the markets we serve.

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results

Retrieved on:

Thursday, September 17, 2020

Medicine, Medical physics, Radiation therapy, Clinical medicine, Brachytherapy, IsoRay, Prostate brachytherapy

RICHLAND, Wash., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced financial results for the fiscal fourth quarter and full-year ended June 30, 2020.

Key Points:

RICHLAND, Wash., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced financial results for the fiscal fourth quarter and full-year ended June 30, 2020.
Revenue for the fourth quarter of fiscal 2020 grew 18% to $2.28 million versus $1.92 million in the prior year comparable period.
Prostate brachytherapy represented 84% of total revenue for the fourth quarter of fiscal 2020 compared to 89% in the prior year comparable period.
Cash, cash equivalents, and certificates of deposits at the end of fiscal 2020 totaled $2.39 million and the Company had no long-term debt.Shareholders equity at the end of fiscal 2020 totaled $5.72 million.

Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate Cancer

Retrieved on:

Tuesday, June 2, 2020

Medicine, Medical physics, Clinical medicine, Cancer, Brachytherapy, Prostate brachytherapy, Radiation therapy, Prostate cancer, External beam radiotherapy, Management of prostate cancer

The authors concluded that the study demonstrates that, Prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control.

Key Points:

The authors concluded that the study demonstrates that, Prostate brachytherapy treated with Cesium-131 achieves excellent long-term biochemical control.
Woods noted that emerging treatment strategies for localized prostate cancer require years of follow-up, given the long natural history of this cancer.
Cesium-131 has the shortest half-life and highest energy of brachytherapy seeds commonly used in the treatment of prostate cancer.
Unlike external beam radiation, Cesium-131 internal radiation therapy is able to deliver a precise dosage and placement of Cesium-131 seeds, leaving healthy tissues and organs undamaged.

Isoray Announces Record Third Quarter Fiscal 2020 Financial Results

Retrieved on:

Tuesday, May 12, 2020

Medicine, Medical physics, Radiation therapy, Clinical medicine, Cancer, Brachytherapy, IsoRay, Prostate cancer, Prostate brachytherapy

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2020 ended March 31, 2020.

Key Points:

RICHLAND, Wash., May 12, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the third quarter fiscal 2020 ended March 31, 2020.
Revenue for the third quarter of fiscal 2020 grew 50% to a record $2.88 million versus $1.92 million in the prior year comparable period.
Prostate brachytherapy represented 84% of total revenue for the third quarter of fiscal 2020 compared to 88% in the prior year comparable period.
Shareholders equity at the end of the third quarter of fiscal 2020 totaled $5.82 million.

Isoray Announces Second Quarter Fiscal 2020 Financial Results

Retrieved on:

Tuesday, February 11, 2020

Medicine, Radiation therapy, Medical physics, Clinical medicine, Cancer, Brachytherapy, IsoRay, Prostate cancer, Prostate brachytherapy

RICHLAND, Wash., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the second quarter fiscal 2020 ended December 31, 2019.

Key Points:

RICHLAND, Wash., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced its financial results for the second quarter fiscal 2020 ended December 31, 2019.
Revenue for the second quarter of fiscal 2020 grew 16% to $2.21 million versus $1.90 million in the prior year comparable period.
Prostate brachytherapy represented 89% of total revenue for the second quarter of fiscal 2020 compared to 89% in the prior year comparable period.
Shareholders equity at the end of the second quarter of fiscal 2020 totaled $6.14 million.

Isoray Announces Record First Quarter Fiscal 2020 Financial Results

Retrieved on:

Tuesday, November 12, 2019

Medicine, Radiation therapy, Medical physics, Cancer, Clinical medicine, Brachytherapy, Prostate cancer, Prostate brachytherapy

Revenue for the first quarter of fiscal 2020 grew 48% to a record $2.32 million versus $1.56 million in the prior year comparable period.

Key Points:

Revenue for the first quarter of fiscal 2020 grew 48% to a record $2.32 million versus $1.56 million in the prior year comparable period.
Prostate brachytherapy represented 90% of total revenue for the first quarter of fiscal 2020 compared to 88% in the prior year comparable period.
Non-prostate brachytherapy revenue in the first quarter of fiscal 2020 was comprised primarily of sales to treat brain, gynecological, colorectal, and other cancers.
Total operating expenses for the first quarter of fiscal 2020 included a change in the estimate of an asset retirement obligation as a result of a lease term extension during the first quarter of fiscal 2020, which decreased total operating expenses by $73,000.